Clinical trials: Tauopathies
Alzheimer Disease
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03444870
- Testing
- Gantenerumab
- Where
- 172 sites in United States, Australia and 13 more
- Volunteers
- 1,053 people
- Sponsor
- Hoffmann-La Roche
Insomnia, Sleep Initiation and Maintenance Disorders
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Modafinil, trade named Provigil, is a medication approved by the Food and Drug Administration for the treatment of narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.
- Conditions
- Insomnia, Sleep Initiation and Maintenance Disorders, Alzheimer Disease
- Trial name
- NCT00626210
- Testing
- modafinil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- VA Palo Alto Health Care System
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
To examine the differences in the capacity to activate microglia in patients with Alzheimer's Disease (AD) compared to age-comparable cognitively normal subjects and younger healthy controls.
- Trial name
- NCT04057807
- Testing
- LPS
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yale University
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Trial name
- ADVANCE-2 (NCT05557409)
- Testing
- AXS-05
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 408 people
- Sponsor
- Axsome Therapeutics, Inc.
Dementia, Alzheimer's Disease
"Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"
A Pilot Study for the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program (HALT-AD). This initial four-months pilot study will focus on at least three educational courses (introduction to…
- Conditions
- Dementia, Alzheimer's Disease, Dementia Prevention
- Trial name
- HALT-AD (NCT05350410)
- Testing
- HALT-AD
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer's Disease
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.
- Trial name
- NCT01614886
- Testing
- Active Comparator, ENA713
- Where
- 50 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Fall, Alzheimer Disease
Falls: A Marker of Preclinical AD
This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages…
- Trial name
- NCT04949529
- Where
- United States
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143).
- Trial name
- NCT00998764
- Testing
- Bapineuzumab 0.5 mg/kg
- Where
- 184 sites in United States, Argentina and 17 more
- Volunteers
- 494 people
- Sponsor
- Pfizer
Apathy, Alzheimer's Disease
Apathy in Dementia Methylphenidate Trial 2
Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, multi-center randomized clinical trial sponsored by National Institutes of Aging involving 200 participants with…
- Trial name
- ADMET2 (NCT02346201)
- Testing
- Methylphenidate
- Where
- 10 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Alzheimer Disease, Dementia
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Alzheimer's disease (AD) often manifests as a memory disorder before dementia develops. Dementia is considered to be present when a person can no longer handle complex activities of daily living, such as managing finances.
- Trial name
- CASL (NCT00880555)
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
A medicine that is FDA-approved for bone marrow stimulation (called Leukine) will be tested for its ability to be tolerated by Alzheimer's disease patients and potentially to improve their memory.
- Trial name
- NCT01409915
- Testing
- Sagramostim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Alzheimer Disease, Presbycusis
Age-related Hearing Loss and Lexical Disorders
In France, Alzheimer's disease accounts for 70 to 80% of the causes of neurocognitive disorders, i.e. 600,000 to 800,000 patients.
- Conditions
- Alzheimer Disease, Presbycusis, Lexical Syntactic Disorder
- Trial name
- LOOP (NCT03638323)
- Testing
- Speech therapy
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - Combo INI+EMPA Trial
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2…
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05081219
- Testing
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Alzheimer's Disease
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
This study evaluated the safety and efficacy of 10 cm^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm^2 for at…
- Trial name
- ADEPT (NCT00561392)
- Testing
- Rivastigmine 5 and 10 cm^2 patch
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Novartis
Alzheimer's Disease
Effects of Simvastatin on Biomarkers
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.
- Trial name
- SimBio (NCT01142336)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Washington
Alzheimer's Disease
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy…
- Trial name
- NCT01767311
- Testing
- Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg
- Where
- 169 sites in United States, Canada and 9 more
- Volunteers
- 856 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00945672
- Testing
- PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg
- Where
- 4 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Pfizer
Alzheimer Disease, Caregiver Stress Syndrome
Learning and Improving Alzheimer's Patient-Caregiver Relationships Via Smart Healthcare Technology
The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships.
- Trial name
- NCT04536701
- Testing
- Mood Monitoring and Behavioral Recommendation System
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Ohio State University